Onc.AI
Onc.AI is a privately held digital health company focused on improving oncology decision-making through AI-powered technology. By utilizing a leading oncology real-world dataset, including diagnostic imaging, EMR, labs, and genomics, Onc.AI is developing AI models aimed at enhancing precision oncology. Their first product assists medical oncologists in making treatment decisions for metastatic lung cancer patients undergoing PD-1 immunotherapy. The company is positioned to significantly impact cancer treatment with its innovative solutions and has received recognition and funding to advance its mission.
Onc.AI
Onc.AI is a privately held digital health company focused on improving oncology decision-making through AI-powered technology. By utilizing a leading oncology real-world dataset, including diagnostic imaging, EMR, labs, and genomics, Onc.AI is developing AI models aimed at enhancing precision oncology. Their first product assists medical oncologists in making treatment decisions for metastatic lung cancer patients undergoing PD-1 immunotherapy. The company is positioned to significantly impact cancer treatment with its innovative solutions and has received recognition and funding to advance its mission.
TL;DR
What they do: AI-driven imaging biomarkers and predictive models to support oncology decision-making and drug development
First product focus: Treatment decision support for metastatic lung cancer patients on PD-1 immunotherapy
Founded / HQ: 2020; San Francisco Bay Area (San Carlos) with presence in Waterloo, Ontario
Stage / funding signal: Raised venture rounds and grant funding (including a Series A and an NCI grant)
Team size: Approximately 25 employees
Company Overview
Problem Domain
Clinical oncology decision support and oncology-focused AI for pharmaceutical/clinical development
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Series A announced Jan 5, 2023; multiple investors listed
Early seed-stage investor activity recorded
Reported NCI grant awarded in October 2024 (~$2.0M reported in some listings)
Investor Signal
“Accomplice; Action Potential Venture Capital; Digitalis Ventures; Frederic Kerrest; Jonathan J. Fleming; KdT Ventures; Life Extension Ventures; MassMutual; National Cancer Institute; Stanley M. Marks; T. Chen Fong; The Blue Venture Fund”